Experts welcome new HIV treatments for kids

New child-friendly formulations of several important antiretroviral medicines were recently approved by the South African Health Products Regulatory Authority. Thabo Molelekwa asks what this means for children living with HIV in South Africa and how long it will take for these medicines to become widely available.

Read More

Over 3million people on new HIV drug, but not all smooth sailing

In 2019, the Department of Health started providing the antiretroviral drug dolutegravir as part of HIV treatment in the public sector. Three years later, close to 3.2 million people in South Africa are taking dolutegravir every day. Even so, the rollout of dolutegravir hasn’t all been smooth sailing. Elri Voigt investigates how the massive undertaking of switching millions of people to a new drug has gone.

Read More

Programme delivers comprehensive HIV prevention and SRH services to learners

Even though the rate of new HIV infections in young women and adolescent girls remains stubbornly high, provision and uptake of pills that can prevent HIV infection have generally been slow and lagging. One potential solution presented at the recent Conference on Retroviruses and Opportunistic Infections is to provide the pills at schools. Tiyese Jeranji reports.

Read More

HPV: What is happening with SA’s other relatively new vaccine programme?

In 2014, South Africa launched an HPV vaccination campaign targeting 9-year-old public school learners in Grade 4. It involves delivering two doses of vaccine six months apart. Laura Owings asks how the campaign is going and what recent real-world HPV vaccine effectiveness data from the United Kingdom might mean for South Africa.

Read More